223 related articles for article (PubMed ID: 31358900)
1. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
[TBL] [Abstract][Full Text] [Related]
3. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
4. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
5. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z
Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544
[TBL] [Abstract][Full Text] [Related]
7. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.
Zhu C; Luong R; Zhuo M; Johnson DT; McKenney JK; Cunha GR; Sun Z
J Biol Chem; 2011 Sep; 286(38):33478-88. PubMed ID: 21795710
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
9. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
10. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
[TBL] [Abstract][Full Text] [Related]
11. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
[TBL] [Abstract][Full Text] [Related]
12. Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells.
He Y; Hooker E; Yu EJ; Cunha GR; Liao L; Xu J; Earl A; Wu H; Gonzalgo ML; Sun Z
Oncogene; 2019 Mar; 38(13):2337-2350. PubMed ID: 30510232
[TBL] [Abstract][Full Text] [Related]
13. Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis.
Wu M; Ingram L; Tolosa EJ; Vera RE; Li Q; Kim S; Ma Y; Spyropoulos DD; Beharry Z; Huang J; Fernandez-Zapico ME; Cai H
J Biol Chem; 2016 Dec; 291(49):25749-25760. PubMed ID: 27760825
[TBL] [Abstract][Full Text] [Related]
14. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
[TBL] [Abstract][Full Text] [Related]
15. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.
Wang Y; Radhakrishnan D; He X; Peehl DM; Eng C
J Clin Endocrinol Metab; 2013 Mar; 98(3):E586-94. PubMed ID: 23386643
[TBL] [Abstract][Full Text] [Related]
16. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Ratliff TL
J Urol; 2005 Sep; 174(3):1149. PubMed ID: 16094083
[No Abstract] [Full Text] [Related]
18. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.
Shin S; Kim TD; Jin F; van Deursen JM; Dehm SM; Tindall DJ; Grande JP; Munz JM; Vasmatzis G; Janknecht R
Cancer Res; 2009 Oct; 69(20):8102-10. PubMed ID: 19789348
[TBL] [Abstract][Full Text] [Related]
19. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
20. The role of tumor suppressor dysregulation in prostate cancer progression.
Dean JL; Knudsen KE
Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
